Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Top Cited Papers
- 6 January 2015
- journal article
- review article
- Published by Annual Reviews in Annual Review of Pharmacology and Toxicology
- Vol. 55 (1) , 489-511
Abstract
Designed ankyrin repeat proteins (DARPins) can recognize targets with specificities and affinities that equal or surpass those of antibodies, but because of their robustness and extreme stability, they allow a multitude of more advanced formats and applications. This review highlights recent advances in DARPin design, illustrates their properties, and gives some examples of their use. In research, they have been established as intracellular, real-time sensors of protein conformations and as crystallization chaperones. For future therapies, DARPins have been developed by advanced, structure-based protein engineering to selectively induce apoptosis in tumors by uncoupling surface receptors from their signaling cascades. They have also been used successfully for retargeting viruses. In ongoing clinical trials, DARPins have shown good safety and efficacy in macular degeneration diseases. These developments all ultimately exploit the high stability, solubility, and aggregation resistance of these molecules, permitting a wide range of conjugates and fusions to be produced and purified.Keywords
This publication has 128 references indexed in Scilit:
- Conformational Coupling across the Plasma Membrane in Activation of the EGF ReceptorCell, 2013
- Architecture and Membrane Interactions of the EGF ReceptorCell, 2013
- Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applicationsAngiogenesis, 2012
- Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunityImmunologic Research, 2011
- Her2-specific Multivalent Adapters Confer Designed Tropism to Adenovirus for Gene TargetingJournal of Molecular Biology, 2011
- Neonatal Fc Receptor: From Immunity to TherapeuticsJournal of Clinical Immunology, 2010
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941Cancer Cell, 2009
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearanceAdvanced Drug Delivery Reviews, 2008
- Ankyrin Repeat: A Unique Motif Mediating Protein−Protein InteractionsBiochemistry, 2006
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004